4-Methylisoquinoline-5-sulfonyl chloride → HCID 9885022, Verbindung
Reaktionsgleichung
C(OC([N:8]1[CH2:14][CH2:13][CH2:12][NH:11][CH:10]([CH3:15])[CH2:9]1)=O)(C)(C)C.CC1CNCCCN1.[Cl:24][S:25]([C:28]1[CH:37]=[CH:36][CH:35]=[C:34]2[C:29]=1[C:30]([CH3:38])=[CH:31][N:32]=[CH:33]2)(=[O:27])=[O:26]>>[ClH:24].[CH3:15][CH:10]1[CH2:9][NH:8][CH2:14][CH2:13][CH2:12][N:11]1[S:25]([C:28]1[CH:37]=[CH:36][CH:35]=[C:34]2[C:29]=1[C:30]([CH3:38])=[CH:31][N:32]=[CH:33]2)(=[O:26])=[O:27]Komponenten
4
Versuchsvorschrift
Using 1.07 g of 4-(tert-butoxycarbonyl)-hexahydro-2-methyl-1H-1,4-diazepine prepared by protecting the 4-position of hexahydro-2-methyl-1H-1,4-diazepine (2.8 g) synthesized in accordance with J. Med. Chem., 1990, 33, 142 and 1.21 g of 5-chlorosulfonyl-4-methylisoquinoline, the procedure of Example 1 was otherwise repeated to provide 0.27 g of the objective compound (white crystals).